long half-life and large variability [Regulatives / Guidelines]
❝ Welcome to the home of funky and funny pharmacokinetics where "Garbage in Gospel out" is day of life.
❝ 1. allowing long washout periods have seen studies with 4 -5 months washout.
Seen a couple as well.
❝ 2. other choice we can imagine is Two stage adaptive study design and including ANCOA in place of ANOVA...
Slippery grounds – nothing published. You are on your own to demonstrate that the Type I Error is controlled. For the FDA and Health Canada likely simulations are sufficient. For the EMA no way.
I’m a fan of TSDs but if you proceed to the second stage it more than doubles the time of study compared to a fixed sample design. With fast to moderate half lives not an issue. But here?
Furthermore, reference-scaling for HVD(P)s in a TSD is not possible. Some tried, all studies were rejected due to potential inflation of the TIE.
Dif-tor heh smusma 🖖🏼 Довге життя Україна!
The quality of responses received is directly proportional to the quality of the question asked. 🚮
- long half-life and large variability martin 2020-07-29 16:57 [Regulatives / Guidelines]
- long half-life and large variability ElMaestro 2020-07-29 21:24
- long half-life and large variability Achievwin 2020-08-12 15:22
- long half-life and large variabilityHelmut 2020-08-12 15:53